PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1662896
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1662896
According to Stratistics MRC, the Global Intramedullary Nails Market is accounted for $767.3 million in 2024 and is expected to reach $1138.7 million by 2030 growing at a CAGR of 6.8% during the forecast period. Intramedullary nails are orthopedic implants used to stabilize bone fractures. Inserted into the medullary canal (hollow center) of a bone, they provide internal fixation, aligning and supporting the bone fragments during healing. Commonly used for femur, tibia, and humerus fractures, these nails come in various designs and materials (titanium, stainless steel) to suit different fracture types and patient needs. They enable early mobilization and reduce the need for external fixation.
According to the World Health Organization (WHO), road traffic injuries cause a substantial burden of disability and mortality globally, with an estimated 1.19 million deaths annually.
Aging population and osteoporosis
The aging global population, particularly individuals over 60, is a key driver for the intramedullary nails market. Conditions such as osteoporosis increase susceptibility to fractures, necessitating advanced orthopedic solutions. With projections indicating that the elderly population will reach 2.1 billion by 2050, the demand for intramedullary nails is expected to grow significantly. These devices provide effective fracture management, enabling faster recovery and improved mobility, which are critical for elderly patient.
High cost of implants
The high cost of intramedullary nails presents a significant barrier to market growth, particularly in developing regions. These implants can be prohibitively expensive for many patients despite their effectiveness, limiting access to potentially life-saving procedures. The impact extends to healthcare providers and facilities, leading to longer recovery periods and worse patient outcomes in cases where cost prevents optimal treatment.
Development customized intramedullary nails
Technological advancements in design and materials, including biodegradable nails, smart nails with integrated sensors, and improved locking mechanisms, are enhancing treatment efficacy and expanding the range of conditions that can be effectively treated. Companies focusing on research and development to bring innovative products to market can differentiate themselves and capture larger market share.
Changes in healthcare reimbursement policies
Limited reimbursement can reduce procedure volumes and hinder market expansion, particularly in regions with constrained healthcare budgets. Inadequate reimbursement rates or restrictions on coverage for intramedullary nail procedures create financial barriers for patients and healthcare providers. Socioeconomic disparities, including disparities in access to healthcare, education, and resources, can influence the demand for orthopedic treatments.
The pandemic significantly impacted the intramedullary nails market, with a 44.6% decline in surgical procedure volumes during peak COVID-19 compared to pre-pandemic levels. Elective surgeries were postponed or cancelled, creating substantial backlogs. Although procedure volumes recovered to 85.8% of pre-pandemic levels in the post-peak period, the expected surge from clearing backlogs has yet to materialize.
The titanium alloy segment is expected to be the largest during the forecast period
The titanium alloy segment is expected to account for the largest market share during the forecast period due to their high strength, lightweight properties, and excellent biocompatibility. These materials reduce stress shielding and promote faster bone healing, making them ideal for intramedullary nails used in trauma surgeries. Additionally, titanium's corrosion resistance and durability ensure long-term implant stability, increasing its adoption among surgeons and healthcare providers. Growing demand for minimally invasive orthopedic procedures further boosts the segment's dominance in the market.
The ambulatory surgical centers (ASCs) segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the ambulatory surgical centers (ASCs) segment is predicted to witness the highest growth rate. ASCs offer cost-effective, same-day surgical procedures, making them an attractive alternative to hospital-based treatments. The increasing preference for outpatient orthopedic surgeries, driven by shorter recovery times and reduced hospital stays, fuels the growth of ASCs. Additionally, advancements in minimally invasive techniques and favorable reimbursement policies for day-care procedures enhance the adoption of intramedullary nails in ASCs, driving their rapid market expansion.
During the forecast period, North America region is expected to hold the largest market share. Factors such as a well-established healthcare infrastructure, high adoption of advanced orthopedic implants, and rising fracture cases among the elderly contribute to the region's dominance. The presence of leading market players and continuous advancements in orthopedic trauma care further strengthen North America's position. Additionally, favorable reimbursement policies and increasing healthcare expenditures support market growth.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. The region's rapid growth is driven by a rising geriatric population, increasing cases of osteoporosis, and growing awareness about advanced trauma care. Expanding healthcare infrastructure, coupled with rising medical tourism in countries like India, China, and Japan, further accelerates market growth. Government initiatives supporting affordable orthopedic treatments and increasing investments in medical device manufacturing enhance the region's potential. As healthcare accessibility improves, the demand for intramedullary nails is expected to surge significantly.
Key players in the market
Some of the key players in Intramedullary Nails Market include Stryker Corporation, DePuy Synthes (Johnson & Johnson), Zimmer Biomet, Smith+Nephew, Medtronic plc, B. Braun Melsungen AG, Orthofix Medical Inc., Wright Medical Group N.V., Orthopaedic Implant Company, Micromed Medizintechnik GmbH, GPC Medical Ltd., MEDIN a.s., Pega Medical Inc., Bioimpianti, IMECO S.A., CarboFix Orthopedics Ltd, AAP Implantate AG and Mizuho OSI, Inc.
In February 2024, Smith+Nephew, the global medical technology company, announces the premiere of its newly acquired CARTIHEAL* AGILI-C* Cartilage Repair Implant alongside the REGENETEN* Bioinductive Implant at the AAOS Annual Meeting, demonstrating its leadership with products that enable biological healing for Sports Medicine. Backed by impressive clinical evidence, both technologies are transforming the way healthcare professionals treat soft tissue repair and helping improve patient outcomes versus the current standard of care.
In January 2024, Stryker announced that it expanded its Gamma4 hip fracture nailing system by adding an intermediate nail. The latest expansion received FDA 510(k) clearance in June 2023. Since its 2022 launch, Gamma4 has been used in more than 19,000 cases across more than 850 facilities. Kalamazoo, Michigan-based Stryker now incorporates the RC Lag screw and an anti-rotation clip with sleeve components in the Gamma4.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.